<amendment session="104" chamber="h" number="735" updated="2013-07-17T07:50:48-04:00">
  <amends type="h" number="2127" sequence="24"/>
  <status datetime="1995-08-04T00:23:00-04:00">fail</status>
  <sponsor id="400357"/>
  <offered datetime="1995-08-03"/>
  <description>Amendment sought to prohibit the National Institute of Health from using funds appropriated in the bill to enter into contractual agreements with drug companies, unless such contracts include a reasonable pricing clause, whereby the drug company agrees to market all drugs developed with tax-payer funded research and development at a reasonable price.</description>
  <purpose>An amendment, printed as amendment No. 63 in the Congressional Record of July 31, 1995, to prohibit the National Institute of Health from using funds appropriated in the bill to enter into contractual agreement with drug companies, unless such contracts include a reasonable pricing clause, whereby the drug company agrees to market all drugs developed with tax-payer funded research and development at a reasonable price. The amendment would allow NIH to waive the requirement if it is determined that a reasonable pricing structure would not be in the public interest.</purpose>
  <actions>
    <action datetime="1995-08-03T22:59:00-04:00">
      <text>Amendment (A024) offered by Mr. Sanders.</text>
    </action>
    <vote datetime="1995-08-04T00:23:00-04:00" how="roll" result="fail" roll="624">
      <text>On agreeing to the Sanders amendment (A024) Failed by recorded vote: 141 - 284 (Roll no. 624).</text>
    </vote>
  </actions>
</amendment>
